Pfizer (PFE) Finished Goods (2009 - 2019)

Pfizer (PFE) has reported Finished Goods for 11 consecutive years, with $2.3 billion the latest figure, recorded in Q1 2019.

• On a quarterly basis, Finished Goods fell 19.42% year-over-year to $2.3 billion in Q1 2019; TTM through Mar 2019 was $2.3 billion, a 19.42% decrease from a year earlier, with the FY2018 full-year figure at $2.3 billion, down 21.54% from the prior year.
• Finished Goods was $2.3 billion for Q1 2019 at Pfizer, up from $2.3 billion in the prior quarter.
• Over five years, Finished Goods peaked at $2.9 billion in Q4 2017 and troughed at $1.8 billion in Q2 2015.
• A 5-year average of $2.5 billion and a median of $2.7 billion in 2016 frame the typical range for Finished Goods.
• Across the five-year window, Finished Goods retreated 24.86% in 2015 and jumped 49.89% in 2016, its largest moves.
• Over 5 years, Finished Goods stood at $2.7 billion in 2015, then fell by 15.51% to $2.3 billion in 2016, then grew by 25.73% to $2.9 billion in 2017, then decreased by 21.54% to $2.3 billion in 2018, then rose by 1.11% to $2.3 billion in 2019.
• The last three Finished Goods figures came in at $2.3 billion (Q1 2019), $2.3 billion (Q4 2018), and $2.6 billion (Q3 2018), per Business Quant data.